Study Details

Back
Study ID 9785-CL-0003
Study Title A Phase I, Open-label, Randomized, Parallel, Relative Bioavailability Study Comparing a Capsule and a Tablet Formulation of Enzalutamide Following Multiple Once Daily Doses of 160 mg Enzalutamide in Male Subjects with Prostate Cancer
Clinicaltrials.gov Identifier NCT01902251
Compound Name MDV3100 / enzalutamide
Medical Indication or Disease Prostate cancer
Study Sponsor Astellas Pharma Europe BV
Collaborator Medivation LLC, a wholly owned subsidiary of Pfizer Inc.
Study Start Date 13-Dec-2012
Study Completion Date 25-Oct-2013
Clinical Study Result
Select the language
English
Plain Language Summary
Select the language
English

QUICK SEARCH

USEFUL LINKS